<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32447548</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>267</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Riluzole prescribing, uptake and treatment discontinuation in people with amyotrophic lateral sclerosis in Scotland.</ArticleTitle><Pagination><StartPage>2459</StartPage><EndPage>2461</EndPage><MedlinePgn>2459-2461</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-020-09919-9</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jayaprakash</LastName><ForeName>Kiran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Glasmacher</LastName><ForeName>Stella A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-1165-9153</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beswick</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Arpan R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-5715-5025</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dakin</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, NHS Lothian, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Suvankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK. suvankar.pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK. suvankar.pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK. suvankar.pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute, University of Edinburgh, Edinburgh, UK. suvankar.pal@ed.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CARE-MND Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MEHTA/JUL17/948-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R001162/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012606" MajorTopicYN="N" Type="Geographic">Scotland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028761" MajorTopicYN="N">Withholding Treatment</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Colville</LastName><ForeName>Shuna</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davenport</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorrie</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duncan</LastName><ForeName>Callum</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connor</LastName><ForeName>Myles</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolezal</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lassak</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benvenga</LastName><ForeName>Antonella</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Artal</LastName><ForeName>Javier Carod</ForeName><Initials>JC</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32447548</ArticleId><ArticleId IdType="pmc">PMC7359150</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09919-9</ArticleId><ArticleId IdType="pii">10.1007/s00415-020-09919-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585&#x2013;591. doi: 10.1056/nejm199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, Lepore V, Simone IL, Lamberti P, Serlenga L, Logroscino G. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol. 2007;14(3):262&#x2013;268. doi: 10.1111/j.1468-1331.2006.01575.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2006.01575.x</ArticleId><ArticleId IdType="pubmed">17355545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin Drug Saf. 2004;3(6):525&#x2013;534. doi: 10.1517/14740338.3.6.525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.3.6.525</ArticleId><ArticleId IdType="pubmed">15500412</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE (2001) Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease. 20. National Institute for Health and Care Excellence. URL: www.nice.org.uk/guidance/ta20</Citation></Reference><Reference><Citation>Leighton D, Newton J, Colville S, Bethell A, Craig G, Cunningham L, Flett M, Fraser D, Hatrick J, Lennox H, Marshall L, McAleer D, McEleney A, Millar K, Silver A, Stephenson L, Stewart S, Storey D, Stott G, Thornton C, Webber C, Gordon H, Melchiorre G, Sherlock L, Beswick E, Buchanan D, Abrahams S, Bateman A, Preston J, Duncan C, Davenport R, Gorrie G, Morrison I, Swingler R, Chandran S, Pal S. Clinical audit research and evaluation of motor neuron disease (CARE-MND): a national electronic platform for prospective, longitudinal monitoring of MND in Scotland. Amyotroph Lateral Scler Front Degener. 2019;20(3&#x2013;4):242&#x2013;250. doi: 10.1080/21678421.2019.1582673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1582673</ArticleId><ArticleId IdType="pubmed">30889975</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison KE, Krishna U, Worku DA. Overview and audit against Motor Neurone Disease (MND) Association guidelines of a MND consultant&#x2019;s practice over the last 3 years at the [Hospital] Res Medica. 2017;24(1):65&#x2013;74. doi: 10.2218/resmedica.v24i1.1563.</Citation><ArticleIdList><ArticleId IdType="doi">10.2218/resmedica.v24i1.1563</ArticleId></ArticleIdList></Reference><Reference><Citation>Centre HaSCI (2014) Use of NICE-appraised medicines in the NHS in England&#x2014;2012, experimental statistics.</Citation></Reference><Reference><Citation>Nygren I, Antonova K, Mattsson P, Askmark H. The ALS/MND prevalence in Sweden estimated by riluzole sales statistics. Acta Neurol Scand. 2005;111(3):180&#x2013;184. doi: 10.1111/j.1600-0404.2005.00384.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2005.00384.x</ArticleId><ArticleId IdType="pubmed">15691287</ArticleId></ArticleIdList></Reference><Reference><Citation>Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R, Rowe D, Schultz D, Edis R, Needham M, Macdonnell R, McCombe P, Birks C, Kiernan M. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ open. 2016;6(9):e012054. doi: 10.1136/bmjopen-2016-012054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-012054</ArticleId><ArticleId IdType="pmc">PMC5051496</ArticleId><ArticleId IdType="pubmed">27694488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther. 2011;17(1):4&#x2013;31. doi: 10.1111/j.1755-5949.2009.00116.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2009.00116.x</ArticleId><ArticleId IdType="pmc">PMC6493865</ArticleId><ArticleId IdType="pubmed">20236142</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>